Multiple Sclerosis Relief

What Multiple Sclerosis Clients Say

“ These improvements are immeasurable to someone who has multiple sclerosis……….I feel very lucky that I was able to be a part of the research of the EnerMed device.”
S.M. WA

“Thanks be to God, Todd Richards, yourself and the rest of the team responsible for me being a recipient of the EnerMed device which, for the past seven months, has contributed a better quality of life for me.”
V.G. WA

Extract from a letter to Director of Device Evaluation, FDA:

“As a victim of MS, I went to Vancouver, B.C. in June (to have) an EnerMed set for my own particular needs.  I have had a total relief from the spasticity………..  Please for the benefit of the 30 million migraine sufferers and 300,000 M.S. patients in this country, expedite your approval of this device.”
B.W. Ohio.

“I was a participant of the EnerMed MS research project…..I found that I really benefited from your product and would like to purchase an EnerMed.”
S.W. New Jersey

“I am extremely thankful for all you have done to make these EnerMed devices…….I can’t even tell you how grateful I am.  When I compare myself with how I felt before starting this I am totally amazed.”
J.B. New Jersey

"...Bladder control, less pins and needles in left hand and foot, fatigue relief.....
K.H., Ohio

"...Fatigue is a thing of the past, spasticity or jerking of legs during sleep has stopped. More sure footed when walking and can go longer distance
Mr. L. E.

"...More energy, physically stronger, more endurance, bladder problems have ceased...."
Ms. S.N. Washington

 "Improved balance and cognitive ability"
G.A. British Columbia

Brief Summary of EnerMed Multiple Sclerosis Research

In 1996 Dr. Todd Richards, a Neurophysicist at the University of Washington conducted a double-blind, placebo controlled study on the effects of the EnerMed Therapy on symptoms of Multiple Sclerosis.(1) This study was supported by a grant from The United States National Institutes of Health, Neurologic and Stroke Division.

30 clinically diagnosed MS patients were enrolled. 15 subjects were randomly assigned to both the active therapy group and to the control group. 

The MS Performance Scale (MSPS)(2) is a summed composite of disability in eight areas: fatigue, cognitive function, mobility, spasticity, hand function, bladder control, sensory symptoms and vision.  The MSPS was the primary outcome measure in this study.

The treatment period was two months.  At the completion of the study, subjects from the active treatment group showed statistically significant improvements in their MSPS.

The positive results of the above study prompted the Multiple Sclerosis Association of  America to fund a multi-site, double-blind placebo controlled, crossover study.  Research sites were in Virginia, New Jersey and Washington State.   Primary outcome measures relating to fatigue, bladder control, spasticity and pain were taken from the MS Quality of Life Inventory (MSQLI) (4)  Secondary outcome measures utilized the MSPS and a daily diary rating of spasticity and bladder control. Subjects received four weeks of active therapy and four weeks of sham therapy separated by a two-week wash out period. 117 subjects completed both stages of the study.

Results were assessed using paired t-tests after subtracting baseline scores from active and placebo treatment scores.  Two of the four MSQLI scores (fatigue and spasticity) showed significant improvement. 

A Quality of Life composite from the MSQLI (fatigue, spasms and pain) also showed significant treatment benefits.(5)

134 MS patients replied to a survey conducted by Energy Medicine Developments.  We asked responders to rate the effectiveness of the EnerMed Therapy on their symptoms.  78% of responders said the EnerMed gave them positive results.  45% rated the therapy as “very effective” while 22% reported no benefits.

• Richards TL, Lappin, MS, Acosta-Urquidi J, et al:  Double-blind study of pulsing  magnetic field effects on multiple sclerosis.

J Alt Complement Med 1997; 3:21-29

• Schwartz CE, Vollmer T, Lee H.  Reliability and validity of two self-report measures of impairment and disability for MS. 

North American Research Consortium on Multiple Sclerosis Outcomes Study Group.  Neurology 1999; 52: 63-70. 

• Lappin MS, Lawrie FW, Richards TL, Kramer ED (2002). Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life.: A double-blind placebo controlled trail. Alternative Therapies in Health and Medicine, 9(4): 38-48

• Rivto PG, Fischer JS, Miller DM, et al:  Multiple Sclerosis Quality of Life Inventory: A User’s Manual. New York: National Multiple Sclerosis Society, 1997.

• Lappin, MS. Non-Invasive pulsed electromagnetic therapy for migraine and multiple sclerosis. In PJ Rosch and M Markov (Eds), Clinical Applications of Bioelectromagnetic Medicine. New York: Marcel Dekker Publishing 2004.  277-291

To Top